BMS conducting Phase I/II trial with Mekinist and Opdivo, with or without Yervoy

Bristol-Myers Squibb Co. (NYSE:BMY) will conduct a Phase I/II trial evaluating its PD-1 inhibitor Opdivo nivolumab with or without Yervoy ipilimumab in combination with Mekinist trametinib from Novartis AG (NYSE:NVS; SIX:NOVN). The trial will evaluate the drugs in metastatic colorectal cancer patients with microsatellite stable tumors where the tumors are proficient in mismatch repair...